Louise Berg has a basic training in biology from Stockholm University and did her doctoral studies at the Karolinska Institutet, Stockholm, within the field of inflammation, obtaining a PhD in 2000. She spent the following 10 years first as a post doctoral fellow and then as a group leader studying viral infections and natural killer cell biology at the Karolinska Institutet. Following this, Louise was recruited to lead a collaboration between Karolinska Institutet and the pharmaceutical company Novo Nordisk. As such, her function was to coodinate the work characterizing target expression and function in cells from patients with inflammatory diseases. She was also involved in organizing the process of cloning and producing patient derived monoclonal antibodies, from patients with rheumatoid arthritis.
The Tissue Platform workgroup within autoimmune inflammatory diseases at Karolinska Institutet studies the effects of probes in cell assays relevant for the diseases we study, ie systemic lupus erythematosus, idiopathic inflammatory myositis, systemic sclerosis and inflammatory bowel disease. The cell assays are based on blood samples or tissue biopsies from these patients, and readouts are either specific, such as antibody production or the production of proinflammatory cytokines, or wider, such as proteomic effects of the probes. The effect of SGC probes, or probes obtained in collaboration with academic groups or industry, are screened using these assays.